High Court to Review Myriad (MYGN) Patent on Genes
Tweet Send to a Friend
Get Alerts MYGN Hot Sheet
Trade MYGN Now!
Shares of generic drug maker Myriad Genetics Inc. (Nasdaq: MYGN) experienced volatility on Friday when news broke that the U.S. high court was going decide whether human genes can be patented.
Myriad Genetics holds patents on two genes linked to hereditary breast and ovarian cancer.
In August the U.S. Federal Circuit Court of Appeals upheld the biotechnology company's right to patent specific genes that account for inherited forms of the two cancers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Myriad Genetics holds patents on two genes linked to hereditary breast and ovarian cancer.
In August the U.S. Federal Circuit Court of Appeals upheld the biotechnology company's right to patent specific genes that account for inherited forms of the two cancers.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Intuitive Surgical (ISRG) Jury Reaches Positive Verdict in Robot Case; Shares Rise
- Headline, Performance Risk Pressure SAC Capital; May Close to New Investors
- Major ResCap Creditor MBIA (MBI) Trades Higher on Ally Settlement
Create E-mail Alert Related Categories
Litigation
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
